Details

Kontrola avtomobilskih zavarovanj : diplomsko delo visokošolskega programa
ID Kobe, Mateja (Author), ID Pevcin, Primož (Mentor) More about this mentor... This link opens in a new window

.pdfPDF - Presentation file, Download (627,39 KB)
MD5: 3F18EF3580C7B63694BF9007CC1CDCFC
PID: 20.500.12556/rul/ec9cc1ae-5e85-45a0-a125-8945e398dc7e

Language:Slovenian
Keywords:avtomobilsko zavaraovanje, zavarovalnice, zavarovalstvo, diplomske naloge
Work type:Bachelor thesis/paper
Typology:2.11 - Undergraduate Thesis
Organization:FU - Faculty of Administration
Place of publishing:Ljubljana
Publisher:[M. Kobe]
Year:2010
Number of pages:V, 50 str.
PID:20.500.12556/RUL-21250 This link opens in a new window
UDC:368.212(043.2)
COBISS.SI-ID:3431342 This link opens in a new window
Publication date in RUL:11.07.2014
Views:4553
Downloads:306
Metadata:XML DC-XML DC-RDF
:
KOBE, Mateja, 2010, Kontrola avtomobilskih zavarovanj : diplomsko delo visokošolskega programa [online]. Bachelor’s thesis. Ljubljana : M. Kobe. [Accessed 25 March 2025]. Retrieved from: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=eng&id=21250
Copy citation
Share:Bookmark and Share

Similar documents

Similar works from RUL:
  1. ǂThe ǂimportance of cancer stem cells and epithelial-mesenchymal transition in the progression of non-small cell lung cancer
  2. Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer
  3. Study of phosphatidylethanolamine N-methyltransferase gene expression in non-small cell lung cancer tissue
  4. Usefulness of immunohistochemically determined epidermal growth factor receptor mutations in lung cancer
  5. Diabetes mellitus and physical activity
Similar works from other Slovenian collections:
  1. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer
  2. Outsourcing predictive biomarker testing in non-small cell carcinoma
  3. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  4. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  5. NSCLC molecular testing in Central and Eastern European countries

Back